araag2/HINT huggingface dataset:
Clinical trial NCT01918332 (phase 3, status: completed)
Conditions: hypertension,, hyperlipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: valsartan 160mg, rosuvastatin 20mg, valsartan 160mg placebo, rosuvastatin 20mg placebo
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Patient aged 20-80 years who has hypertension and hyperlipidemia

          2. Patient who has a Hypertension

          3. Patient who has a Hyperlipidemia according to NCEP-ATP III guideline(2004)

          4. Patient who signed the Informed Consent Form after receiving an explanation on the
             purpose, methods, and effect of the study

        Exclusion Criteria:

          1. If blood pressure and fasting serum lipid level measured at screening and Visit 2 (0
             week) satisfy the following criteria 1) sitSBP≥180mmHg or sitDBP≥110mmHg (For high
             risk group, sitSBP≥ 160mmHg or sitDBP ≥100mmHg ) 2) LDL-C>250mg/dL , or TG≥ 400mg/dL

          2. If sitSBP difference between the right and left arms >20mmHg or sitDBP difference
             between the right and left arms > 10mmHg at screening

          3. When blood pressure is repeatedly measured from the selected arm at screening, if
             sitSBP difference ≥ 20mmHg or sitDBP difference ≥10mmHg

          4. Patient with orthostatic hypotension accompanying symptoms at screening (decrease in
             sitDBP ≥10mmHg or decrease in sitSBP ≥ 20mmHg )
Clinical trial NCT01204294 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: linagliptin, linagliptin, metformin, metformin, linagliptin, linagliptin, linagliptin
SMILES: [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CSCC[C@H](N)C(O)=O, CSCC[C@H](N)C(O)=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1
Eligibility criteria:

        Inclusion criteria:

          1. Diagnosis of type 2 diabetes mellitus

          2. Male and female patients on diet and exercise regimen who are treated with one
             antidiabetic drug

        Exclusion criteria:

          1. Myocardial infarction, stroke, transient ischemic attack, or pulmonary embolism

          2. Impaired hepatic function

          3. Glitazone, glinide, and sulfonylurea group: renal failure or renal impairment defined
             as estimated glomerular filtration rate <30 ml/min (severe renal impairment) at Visit
             1, Biguanide group: renal failure or renal impairment defined as estimated glomerular
             filtration rate <60 ml/min (moderate renal impairment) at Visit 1

          4. Treatment with anti-obesity drugs
Clinical trial NCT01035138 (phase 3, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: semagacestat
SMILES: CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1C2=CC=CC=C2CCN(C)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Meets National Institute of Neurological and Communicative Disorders and
             Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria
             for probable Alzheimer's Disease

          -  Completed semagacestat study LFAN or study LFBC through 88 weeks

          -  Must continue to have a reliable caregiver

          -  Capable of swallowing whole oral medication

          -  Agrees not to participate in other investigational compounds for the duration of study

        Exclusion Criteria:

          -  Meets LFAN or LFBC study discontinuation criteria at the last visit of the LFAN or
             LFBC study
Clinical trial NCT00678392 (phase 3, status: completed)
Conditions: kidney neoplasms
ICD codes: D17.71, D30.00, D30.01, D30.02, D41.00, D41.01, D41.02
Drugs: axitinib (ag-013736), sorafenib
SMILES: CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed renal cell cancer with a component of clear
             cell subtype, with metastasis

          -  Evidence of measurable disease

          -  Must have failed one prior systemic first-line regimen for metastatic renal cell
             cancer

        Exclusion Criteria:

          -  Prior treatment for metastatic renal cell cancer with more that one systemic first
             line therapy

          -  Major surgery less than 4 weeks or radiation less than 2 weeks of starting study drug
Clinical trial NCT01154036 (phase 3, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: ezetimibe 10 mg, atorvastatin, comparator: rosuvastatin
SMILES: O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is at high cardiovascular risk and meets one of the following conditions: has
             never taken lipid-lowering therapy or has been off such therapy for at least 6 weeks;
             or, is currently taking a stable dose of certain lipid-lowering agents

          -  Patient is willing to maintain a cholesterol lowering diet during the study

          -  Female patients receiving non-cyclical hormone therapy have maintained a stable dose
             and regimen for at least 8 weeks and are willing to continue the same regimen during
             the study

        Exclusion Criteria:

          -  Patient is Asian

          -  Patient routinely has more than 2 alcoholic drinks per day

          -  Female patient is pregnant or breastfeeding

          -  Patient has congestive heart failure

          -  Patient has had a myocardial infarction, coronary bypass surgery, angioplasty, or
             acute coronary syndrome within 3 months of screening

          -  Patient has uncontrolled cardiac arrhythmias

          -  Patient has had a partial ileal or gastric bypass or other significant intestinal
             malabsorption

          -  Patient has uncontrolled high blood pressure

          -  Patient has kidney disease

          -  Patient has any disease known to influence blood lipid levels

          -  Patient has any disorders of the blood, digestive system, or nervous system including
             stroke and degenerative disease that would limit study participation

          -  Patient has poorly controlled or newly diagnosed diabetes

          -  Patient is known to be HIV positive

          -  Patient has a history of cancer in the last 5 years, except certain skin and cervical
             cancers
Clinical trial NCT00002882 (phase 3, status: completed)
Conditions: melanoma, skin cancer
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4, C79.2, C44.500, C44.90, D23.9, D48.5, C44.00, C44.301
Drugs: cisplatin, dacarbazine, vinblastine
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, N1C=CN=C1, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically diagnosed malignant melanoma with regional lymph node metastases

          -  Undergone complete lymph node dissection and free of any residual tumor

          -  No greater than 90 days from diagnosis of regional lymph nodes metastases

          -  No distant or resected in-transit metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  10 to 66

          -  66 to 70 if in excellent physical condition

        Performance status:

          -  0-2

        Life expectancy:

          -  At least 12 months

        Hematopoietic:

          -  Hemoglobin greater than 10 g/dL

          -  WBC greater than 3,000/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 1.2 mg/dL

        Renal:

          -  Creatinine no greater than 1.5 mg/dL

        Other:

          -  No serious intercurrent illness that would compromise tolerance of therapy and long
             term survival

          -  Must be able to participate in follow up for minimum of 5 years

          -  No second malignancy except:

               -  In situ cervical cancer

               -  Basal or squamous skin cancer

          -  Must be able to physically and emotionally tolerate biochemotherapy

          -  No history of pulmonary or cardiac dysfunction, e.g., cardiac rhythm disturbance,
             congestive heart failure, coronary bypass, or impaired cardiac ejection fraction

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior immunotherapy with interferon or IL-2

          -  No concurrent immunomodulators

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  No concurrent steroids

        Radiotherapy:

          -  Prior adjuvant local radiotherapy allowed for head and neck

        Surgery:

          -  No greater than 8 weeks after definitive surgery for lymph node metastases

        Other:

          -  No concurrent nonsteroid anti-inflammatory drugs, or other prostaglandin synthetase
             inhibitors
Clinical trial NCT00386308 (phase 3, status: completed)
Conditions: menorrhagia, heavy menstrual bleeding
ICD codes: G43.831, G43.839, G43.821, G43.829, N94.9, N94.89
Drugs: tranexamic acid tablets, placebo tablets
SMILES: NC[C@H]1CC[C@@H](CC1)C(O)=O, NC[C@H]1CC[C@@H](CC1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Women with menorrhagia

          -  18-49 years of age

          -  Regularly occurring menstrual periods

        Exclusion Criteria:

          -  History or presence of clinically significant disease or abnormalities that may
             confound the study

          -  History of bilateral oophorectomy or hysterectomy

          -  Hormone therapy
Clinical trial NCT00060996 (phase 3, status: terminated)
Conditions: critical limb ischemia, peripheral vascular disease, foot ulcers, rest leg pain
ICD codes: I73.9, I73.89
Drugs: remodulin® (treprostinil sodium) injection
SMILES: [H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1
Eligibility criteria:

        Patients with Stage III or IV critical limb ischemia due to documented peripheral arterial
        disease with no planned interventional vascular procedures
Clinical trial NCT00549718 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: lurasidone hcl
SMILES: CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
Eligibility criteria:

        Inclusion Criteria:

        To be eligible to enter the study, each patient must comply with the following inclusion
        criteria:

          -  Provide written informed consent and aged between 18 and 75 years of age.

          -  Meets DSM-IV™ criteria for a primary diagnosis of schizophrenia.

          -  Not pregnant, if of reproductive potential agrees to remain abstinent or use adequate
             and reliable contraception for duration of study.

          -  Able and agrees to remain off prior antipsychotic medication for the duration of
             study.

          -  Good physical health on the basis of medical history, physical examination, and
             laboratory screening.

          -  Willing and able to comply with the protocol, including the inpatient requirements and
             outpatient visits.

        Exclusion Criteria:

          -  Considered by the investigator to be at imminent risk of suicide or injury to self,
             others, or property.

          -  Any chronic organic disease of the CNS (other than schizophrenia)

          -  Used investigational compound within 30 days.

          -  Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence
             within the last 6 months.
Clinical trial NCT00449176 (phase 3, status: completed)
Conditions: low back pain
ICD codes: M54.50, M54.51, M54.59
Drugs: tapentadol (cg5503) er, oxycodone cr, placebo
SMILES: CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1, [H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men and non-pregnant, non-lactating women having a diagnosis of Lower Back Pain (LBP)
             of non-malignant origin present for at least 3 months

          -  Patients taking analgesic medications for at least 3 months prior to screening and/or
             dissatisfied with their current therapy

          -  Patients requiring opioid treatment must be taking daily doses of opioid-based
             analgesic, equivalent to < 160 mg of oral morphine

          -  Baseline score of =5 on an 11-point numerical rater scale, calculated as the average
             pain intensity during the last 3 days prior to randomization.

        Exclusion Criteria:

          -  History of alcohol and/or drug abuse in Investigator's judgement

          -  History of significant liver insufficiency

          -  chronic hepatitis B or C, or HIV, presence of active hepatitis B or C within the past
             3 months

          -  Life-long history of seizure disorder or epilepsy

          -  History of malignancy within past 2 years, with exception of basal cell carcinoma that
             has been successfully treated

          -  Uncontrolled hypertension

          -  Patients with severely impaired renal function

          -  Patients with moderate to severly impaired hepatic function or with laboratory values
             reflecting inadequate hepatic function
Clinical trial NCT00102518 (phase 3, status: completed)
Conditions: schizophrenia, bipolar disorder
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: aripiprazole
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Adolescent patients with schizophrenia, or child and adolescent patients with bipolar
             I disorder, manic or mixed episode

        Exclusion Criteria:

          -  Patients with a co-morbid serious, uncontrolled systemic illness

          -  Patients with a significant risk of committing suicide
Clinical trial NCT00458302 (phase 3, status: completed)
Conditions: hiv infections, aids virus, human immunodeficiency virus, acquired immunodeficiency syndrome virus
ICD codes: Z21, B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: darunavir (drv, tmc114), darunavir (drv, tmc114)
SMILES: [H][C@@]12CCO[C@]1([H])OC[C@@H]2OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1, [H][C@@]12CCO[C@]1([H])OC[C@@H]2OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with documented HIV-1 infection

          -  Patients currently receiving HAART for at least 24 weeks

          -  Plasma viral load < 50 copies/mL for at least 24 weeks prior to screening (two results
             must be documented)

          -  Patients taking the same antiretroviral combination for at least 8 weeks before
             screening

          -  Patients and physician's preference to change the current HAART regimen for reasons of
             simplification and/or toxicity

          -  CD4 > 100/mm3 at the start of HAART and > 200/mm3 at screening.

        Exclusion Criteria:

          -  No history of virological failure defined as two consecutive plasma HIV-1 RNA > 500
             copies/mL while on previous or current antiretroviral therapy

          -  No history of any primary PI mutations as defined by the IAS-USA guidelines 2006

          -  No patients co-infected with hepatitis B

          -  No pregnant or breastfeeding women

          -  No active clinically significant disease or life threatening disease or findings
             during screening of medical history or physical examination that, in the
             investigator's opinion, would compromise the patient's safety or outcome of the study.
Clinical trial NCT00434642 (phase 3, status: completed)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: carboplatin, gemcitabine, bevacizumab, placebo
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed Informed Consent Form

          -  Age ≥ 18 years

          -  Documented ovarian, primary peritoneal, or fallopian tube carcinoma that has recurred

          -  No prior chemotherapy in the recurrent setting

          -  Measurable disease

          -  Recovered from prior radiation therapy or surgery

        Exclusion Criteria:

          -  Prior chemotherapy treatment for recurrent ovarian, primary peritoneal, or fallopian
             tube carcinoma

          -  History of abdominal fistula, gastrointestinal perforation (GIP), or intra-abdominal
             abscess

          -  Patients with clinical symptoms or signs of gastrointestinal (GI) obstruction or who
             require parenteral hydration, parenteral nutrition, or tube feeding

          -  Patients with evidence of abdominal free air not explained by paracentesis or recent
             surgical procedure

          -  Current, recent, or planned participation in an experimental drug study

          -  History of systemic bevacizumab (Avastin) or other vascular endothelial growth factor
             (VEGF) or VEGF receptor-targeted agent use

          -  Inadequately controlled hypertension

          -  Prior history of hypertensive crisis or hypertensive encephalopathy

          -  New York Heart Association Class II or greater congestive heart failure (CHF)

          -  History of myocardial infarction or unstable angina

          -  History of stroke or transient ischemic attack (TIA)

          -  Known central nervous system (CNS) disease except for treated brain metastasis

          -  Significant vascular disease or recent peripheral arterial thrombosis

          -  History of hemoptysis

          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of
             therapeutic anticoagulation)
Clinical trial NCT00614120 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: liraglutide, placebo, liraglutide, liraglutide, glimepiride, metformin, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1, CSCC[C@H](N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes

          -  Subjects diagnosed with type 2 diabetes and treated with one or more oral antidiabetic
             drugs (OADs) for the last 3 months

          -  HbA1c: 7.0-11.0% (both incl.) for subjects on OAD alone

          -  HbA1c: 7.0-10.0 % (both incl.) for subjects on OAD combination therapy

          -  BMI less than 45.0 kg/m^2

        Exclusion Criteria:

          -  Treatment with insulin within the last 3 months prior to the trial

          -  Impaired liver or/and renal function

          -  Significant cardiovascular disease over the last 6 months

          -  Known retinopathy or maculopathy

          -  Recurrent major hypoglycaemia or hypoglycaemic unawareness
Clinical trial NCT00114361 (phase 3, status: completed)
Conditions: hepatitis b
ICD codes: B18.0, B18.1, B19.10, B19.11, B17.0, B16.0, B16.1
Drugs: ribavirin, peginterferon alpha 2a
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic hepatitis B

          -  Biopsy performed within one year prior to screening or during screening

          -  ALT > 1.5 x ULN

          -  HBeAg negative, anti-HBeAg positive

          -  HBV DNA > 10E5 copies/ml

          -  Age 18-70 years

          -  Written informed consent

          -  Hepatic imaging without evidence of HCC

          -  All fertile males and females must be using two forms of effective contraception

        Exclusion Criteria:

          -  Antiviral therapy against HBV within the previous 6 months; treatment with any
             investigational drug within 30 days of entry to this protocol

          -  Severe hepatitis activity as documented by ALT > 10 x ULN

          -  Advanced liver disease

          -  Pre-existent leucopenia or thrombopenia

          -  Co-infection with HCV,HDV or HIV

          -  Other acquired or inherited causes of liver disease

          -  Alpha fetoprotein > 50 ng/ml.

          -  Evidence of severe renal disease

          -  Hyper- or hypothyroidism

          -  Significant cardiovascular or pulmonary dysfunction, malignancy,immunodeficiency
             syndromes

          -  Immune suppressive treatment within the previous 6 months

          -  Contra-indications for alpha-interferon therapy

          -  Pregnancy, breast-feeding

          -  Any medical condition requiring chronic systemic administration of steroids

          -  Substance alcohol or drug abuse

          -  Subjects with clinically significant retinal abnormalities

          -  Subjects with clinically significant hearing abnormalities

          -  Hemoglobinopathies

          -  Subjects with known hypersensitivity to ribavirin
Clinical trial NCT00416910 (phase 3, status: terminated)
Conditions: chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: fludarabine, cyclophosphamide, mitoxantrone
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O
Reason stopped: 
    low recruitment
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Confirmed relapsed and advanced chronic lymphocytic leukemia (CLL)

               -  Binet stage B or C disease with rapid disease progression, enlarged lymph nodes
                  and organs, or severe B-symptoms

          -  No prior non-response to fludarabine combination therapy

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-3

          -  Life expectancy > 6 months

          -  No severe organ dysfunction

          -  No other prior or concurrent neoplasm, autoimmune hemolytic anemia, or
             thrombocytopenia

        PRIOR CONCURRENT THERAPY:

          -  No more than three previous treatment regimens for CLL (fludarabine allowed)